MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Uroplasty, Vision-Sciences merge as Cogentix

Uroplasty, Vision-Sciences merge as Cogentix

By

Uroplasty, Vision-Sciences merge as Cogentix

Uroplasty (NSDQ:UPI) and Vision-Sciences (NSDQ:VSCI) yesterday closed their merger as expected, in the process re-branding as Cogentix Medical (NSDQ:CGNT).

Shares of the new entity, which hit the market today, were down 8.0% to $1.61 from their $1.85-per-share open in mid-day activity.

The new company will focus primarily on diagnosing and treating urologic conditions. Cogentix’s debut follows approval of the merger by shareholders of both Uroplasty and Vision-Sciences March 30; the deal was 1st announced last December.

Uroplasty’s Minnetonka, Minn., home base will become Cogentix’s new U.S. headquarters, the company said, with Uroplasty CEO . Rob Kill at the helm.

Expectations are that Cogentix will produce about $50 million in revenue for the fiscal year beginning today. The combination will also save about $3 million, according to a press release.

Kill, in a statement, said "we remain highly confident in the future growth prospects of Cogentix Medical and look forward to working with the team members of the former Vision-Sciences to complete our integration plans and to release the significant synergies the merger is expected to create."

Cogentix’s products include endoscopy tools that rely on the EndoSheath sterile and disposable microbial barrier, and the Urgent PC neuromodulation system, which is FDA-cleared to treat overactive bladder.

In case you missed it

RSS From Medical Design & Outsourcing

  • NIH launches $9.8M neuromodulation competition
    The National Institutes of Health (NIH) announced today that it launched the first phase of its Neuromod Prize competition. Neuromod Prize, a $9.8 million competition, aims to accelerate the development of neuromodulation therapies. NIH seeks scientists, engineers and clinicians to submit novel concepts and clinical development plans to demonstrate solutions for stimulating the peripheral nervous… […]
  • Junkosha boosts production of PTFE liners and FEP-based heat shrink
    Junkosha announced today that it plans to double production capacity to meet shortages of PTFE liners and FEP-based heat shrink for catheter manufacturers. Both OEMs and contract manufacturers in the catheter space are stressed from shortages in the global supply of vital components, according to the Japanese maker of sophisticated fluoropolymer application technologies. “We believe this… […]
  • Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
    With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a major regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple. As the new year gets underway, expectations for the… […]
  • Former Zimmer Biomet executive has a new job
    Carrie Nichol, the former chief accounting officer of Zimmer Biomet (NYSE:ZBH), has a new job outside of the medtech industry. Nichol, who also served as vice president, controller and principal accounting officer at Zimmer Biomet, is now a VP and controller at Minnetonka, Minnesota-based Cargill. Her departure was among the many notable medtech executive moves… […]
  • Employees say Intuitive, Boston Scientific, J&J, Medtronic are among the best places to work in 2022
    Intuitive Surgical, Boston Scientific, Johnson & Johnson and Medtronic were recently named by Glassdoor as Best Places to Work in 2022 based on employee reviews. Each year, Glassdoor uses feedback that employees have shared on the website over the past 12 months to compile a list of the best places to work for the upcoming… […]
  • Medtronic’s M&A strategy explained by CFO Karen Parkhill
    When Medtronic CFO and EVP Karen Parkhill looks back at the medical device manufacturer’s performance through the COVID-19 pandemic, she recalls a key decision that rankled investors but paid off in the long run. “When I first joined Medtronic, it was shortly after the Covidien merger and we had taken on a lot of debt… […]
  • Loftware acquires Prisym ID
    Loftware announced that it acquired Prisym ID, a provider of regulated content and label management solutions. Prisym ID focuses on clinical trials, medical device and pharmaceutical labeling, with the acquisition set to expand Loftware’s enterprise labeling solution offerings for the medical device and pharmaceutical industries while enhancing Loftware’s end-to-end, cloud-based labeling platform with advanced clinical… […]
  • BD, Pfizer, Wellcome want to improve hospitals’ antimicrobial practices
    BD (NYSE:BDX) announced yesterday that it will collaborate with Pfizer (NYSE:PFE) and Wellcome to advance antimicrobial stewardship practices. The collaboration builds on ongoing efforts to advance the role of diagnostics in addressing the challenge of antimicrobial resistance (AMR), according to a news release. The companies will survey existing diagnostic practices to highlight benefits and gaps… […]
  • iRhythm CEO considers costs on the path to profitability
    Fresh off positive reimbursement news for its Zio remote external electrocardiogram monitoring device, the CEO of iRhythm Technologies (NSDQ:IRTC) doesn’t just have revenue on his mind. iRhythm President and CEO Quentin Blackford — the former Dexcom COO who replaced Mike Coyle in September — said his company will need to keep costs under control as it… […]
  • Integer Holdings makes additions to its executive team
    Integer Holdings today announced that it has appointed three new executives to its leadership team. The appointments come as part of a planned transition due to retirements. Margaret Cathy is being promoted to senior VP of quality and regulatory affairs; Andrew Senn is being promoted to senior VP of strategy and business development and McAlister… […]
  • Healthcare venture funding boomed in 2021; expect a slowdown in 2022
    An all-time-high $86 billion of venture capital investments in the U.S. and Europe last year bested 2020’s record haul by more than 30% and grew more than 150% from 2019, according to a new analysis by Silicon Valley Bank. After record-setting quarters in the first half, however, VC investment slowed due to poor performing biopharma… […]

Leave a Reply